Find clinical trials for Adenocarcinoma in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma

Cancer

Pancreatic Cancer

Colorectal Cancer

Stomach Cancer

Esophageal Cancer

Non-Small-Cell Lung Carcinoma

Adenocarcinoma trials near Toronto, ON, CAN:

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

This study is being done to answer the following question:Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug...

Enrolling

Gastroesophageal Adenocarcinoma

Drug: Zanidatamab

Drug: Paclitaxel

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 14 other locations

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.

Active, not recruiting

Pancreatic Adenocarcinoma

Drug: Gemcitabine

Drug: Nab-paclitaxel

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 26 other locations

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC)....

Active, not recruiting

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Drug: Oxaliplatin

Drug: Fluorouracil

Phase 2

Jazz Pharmaceuticals

Toronto, Ontario, Canada and 20 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting

Advanced Upper Gastrointestinal Tract Adenocarcinoma

Drug: Domvanalimab

Drug: Zimberelimab

Phase 3

Arcus Biosciences

Toronto, Canada and 203 other locations

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...

Enrolling

Non-small Cell Lung Cancer

Drug: Pemetrexed

Drug: Rilvegostomig

Phase 3

AstraZeneca

Newmarket, Ontario, Canada and 195 other locations

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling

Gastroesophageal Junction Cancer

Gastric Cancer

Drug: AZD0901

Drug: Docetaxel

Phase 3

AstraZeneca

Toronto, Ontario, Canada and 171 other locations

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC (IMCODE003)

mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...

Enrolling

Adenocarcinoma, Pancreatic Ductal

Drug: mFOLFIRINOX

Drug: Autogene cevumeran

Phase 2

Genentech

Toronto, Ontario, Canada and 44 other locations

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting

Advanced/Metastatic Gastroesophageal Adenocarcinoma

Drug: 5-FU

Biological: Lenvatinib

Phase 3

Merck Sharp & Dohme (MSD)

Hamilton, Ontario, Canada and 176 other locations

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical st...

Active, not recruiting

Metastatic Gastric Adenocarcinoma or Cancer

Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer

Drug: fluorouracil

Drug: zolbetuximab

Phase 3

Astellas

Toronto, Ontario, Canada and 219 other locations

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzum...

Enrolling

Gastroesophageal Adenocarcinoma

Esophageal Adenocarcinoma

Drug: Tislelizumab

Drug: Capecitabine

Phase 3

Jazz Pharmaceuticals

Toronto, Canada and 321 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Adenocarcinoma in .css-epvm6{white-space:nowrap;}Toronto, ON

Related conditions:

Adenocarcinoma trials near Toronto, ON, CAN:

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC (IMCODE003)

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

Find clinical trials for Adenocarcinoma in Toronto, ON